Back to Dashboard

National Biopharma Alliance

PharmaceuticalsBiologicsRare Disease
40 provisions tracked
7 positive
22 negative
3 conflict
NegativeSec. CMS-2027-01 · CMS Medicare Drug Price Negotiation — 2027 Expansion

Nexavar-X (Sorafenib Extended-Release) — Oncology Biologic

Apex Therapeutics' flagship product — 47% of total revenue at risk. Under 50% negotiation scenario, operating margin drops from 22% to 8%.

ACTION: Priority engagement with Cassidy-Menendez amendment sponsors to secure small biotech exemption
$2.1B annual revenue (47% of Apex total)
NegativeSec. CMS-2027-02 · CMS Medicare Drug Price Negotiation — 2027 Expansion

Immunara / Immunara-SC — Autoimmune Biologics

Dual-product exposure means Cascade cannot shift resources between programs. CEO characterized this as existential threat.

ACTION: Coordinate joint lobbying strategy with Cascade CEO and Elizabeth Lee's health team
$1.8B combined annual revenue
NegativeSec. CMS-2027-03 · CMS Negotiation + FDA Accelerated Approval Reform

GeneVault Therapy — Rare Disease Gene Therapy

NovaPharma faces 55-70% NPV reduction from combined CMS pricing + FDA confirmatory study costs ($45-80M additional).

ACTION: Lead dual-pressure narrative in Cassidy-Menendez amendment advocacy
$680M annual revenue (43% of NovaPharma total)
NegativeSec. FDA-2026-AR · FDA Regulatory Reform

FDA Accelerated Approval Reform — Post-Market Evidence Requirements

Multiple NBA members have accelerated approval products. 180-day initiation requirement strains R&D budgets.

ACTION: File coordinated public comments across all affected NBA members within 60-day window
Est. $45-80M additional cost per drug
NegativeSec. CMS-2027-04 · CMS Medicare Drug Price Negotiation — 2027 Expansion

NeuroCalm XR — CNS / Psychiatric Medication

MindBridge Pharmaceuticals (NBA member) — sole product on negotiation list. 35% of company revenue at risk.

ACTION: Include in small biotech exemption advocacy — MindBridge qualifies under $200M Medicare Part B threshold
$890M annual revenue
PositiveSec. IRA-ESOP · Legislative — Tax/Employment

Retirement Security Enhancement Act — ESOP Expansion Impact on Health Sector

3 small biotech NBA members exploring ESOP structures. Tax credit could offset some revenue pressure from CMS negotiation.

ACTION: Connect interested NBA members with Noelle Montaño's tax practice for ESOP structuring
$50M small business ESOP formation fund